Melphalan flufenamide (melflufen) is approved in Europe for relapsed/refractory multiple myeloma, but the FDA withdrew its ...

[80] Bone disease is a hallmark of multiple myeloma (MM), associated with bone pain, pathological fractures requiring surgery and/or radiation to bone, spinal cord compression and hypercalcemia.

Multiple myeloma accounts for about 10% of all ... those with high-risk cytogenetics, and patients with extramedullary disease. When the FDA approved the first CAR T-cell therapy for use in ...

Were exposed to pesticides. We do not know what causes MGUS. There may be a link to autoimmune diseases, genetics, or environmental factors. Like multiple myeloma, MGUS starts in a type of white blood ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, ...

An obvious synergistic effect was demonstrated in this bortezomib–alkylator combination, given that the disease ... multiple myeloma, even at the stage of terminal illness with extramedullary ...

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

Real-world data from the University of Catania, Italy, suggest that Pepaxti, a treatment for relapsed, refractory multiple myeloma (RRMM), is effective and well tolerated in heavily pretreated ...

For years, patients have been told that multiple myeloma is treatable but not curable. Yet data continues to accumulate about a subset of patients that remains disease-free for so many years that ...

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...